Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Non-Invasive Gut Tests Could Help Diagnose Inflammatory Bowel Disease and Colon Cancer

By LabMedica International staff writers
Posted on 15 Feb 2024
Print article
Image: Mucus contains vital data to help address inflammatory bowel disease and colon cancer (Photo courtesy of 123RF)
Image: Mucus contains vital data to help address inflammatory bowel disease and colon cancer (Photo courtesy of 123RF)

New research is set to simplify and make gut health monitoring less invasive by focusing on an often-ignored yet readily available source: the mucus in our digestive tract that ultimately becomes part of fecal matter.

Researchers at UBC Okanagan (Kelowna, BC, Canada) have developed a method to analyze vital gut health markers from fecal-adherent mucus, essentially the mucus that adheres to stool. This mucus, typically discarded in stool, is actually rich in data about gut health. The team has pioneered a non-invasive approach to study MUC2, a key protein found in the stool that plays a significant role in gut health. MUC2 is a glycoprotein with numerous sugar chains that creates a protective mucus barrier in the intestines. This barrier is essential for defending the gut against harmful microbes and toxins and is integral to digestive health.

Previously, it was believed that this crucial molecule could only be extracted through invasive and painful methods like biopsies or surgical tissue removal. However, this study has revealed that mucus is a natural component of human stool, meaning it can be painlessly obtained and at levels not possible before at any time and that too non-invasively. A deeper understanding of MUC2 could pave the way for breakthroughs in the treatment and prevention of gut-related diseases, potentially improving the daily health of millions.

“MUC2 is like the silent star in our guts. It’s constantly working to protect us, and its proper functioning is crucial for our overall health,” said researcher Dr. Kirk Bergstrom. “We can use these new methods to visualize mucus-microbiota interactions and how they go wrong in various diseases, like inflammatory bowel diseases and colon cancer.”

Related Links:
UBC Okanagan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.